Dr Arlene Siefker-Radtke (MD Anderson Cancer Center, Houston, USA) and Dr Yohann Loriot (Institut Gustave Roussy, Villejuif, France) discuss the latest emerging treatment options, including targeted therapies from ASCO 2020.
The experts begin the session, by discussing the results from the practice-changing JAVELIN Bladder 100 trial. Dr Loriot notes that these results are exciting and provide a new treatment strategy for advanced urothelial carcinoma patients in the first-line.
Dr Siefker-Radtke and Dr Loriot go onto to discuss the emerging use of targeted therapies in bladder cancer, especially FGFR inhibitors and the latest data presented at the meeting.
Dr Siefker-Radtke outlines the main results from the BLC2001 trial, which is investigating the use of erdafitinib in locally advanced or metastatic urothelial carcinoma.
She also describes the phase Ib/II FORT-2 study, which evaluated the safety and efficacy of another FGFR inhibitor, rogaratinib in combination with atezolizumab. Dr Loriot comments that the strategy used in this trial, which identified FGFR mRNA over-expression could broaden the patient population eligible for this treatment. However, he also warns that the response rate in these patients could be lower.
Dr Siefker-Radtke concludes and states there are various treatment combinations being explored for bladder cancer currently, involving immunotherapy, chemotherapy and targeted agents.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).